scispace - formally typeset
A

Arielle Elkrief

Researcher at Université de Montréal

Publications -  79
Citations -  3000

Arielle Elkrief is an academic researcher from Université de Montréal. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 11, co-authored 40 publications receiving 1297 citations. Previous affiliations of Arielle Elkrief include McGill University Health Centre & McGill University.

Papers
More filters
Journal ArticleDOI

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.

Nicole M. Kuderer, +239 more
- 20 Jun 2020 - 
TL;DR: The outcomes of a cohort of patients with cancer and COVID-19 are characterised and potential prognostic factors for mortality and severe illness are identified and race and ethnicity, obesity status, cancer type, type of anticancer therapy, and recent surgery were not associated with mortality.
Journal ArticleDOI

Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium.

Petros Grivas, +128 more
- 01 Jun 2021 - 
TL;DR: In this article, the authors analyzed a cohort of patients with cancer and coronavirus 2019 (COVID-19) reported to the COVID19 and Cancer Consortium (CCC19) to identify prognostic clinical factors, including laboratory measurements and anticancer therapies.
Journal ArticleDOI

Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade.

Miles C. Andrews, +92 more
- 08 Jul 2021 - 
TL;DR: Profiling of gut microbiota demonstrated a significantly higher abundance of Bacteroides intestinalis in patients with toxicity, with upregulation of mucosal IL-1b in patient samples of colitis and in pre-clinical models, which offer potential new therapeutic angles for targeting toxicity to CICB.
Journal ArticleDOI

Moving towards personalized treatments of immune-related adverse events.

TL;DR: An overview of key cellular and soluble immunological factors mediating irAEs are provided and a model integrating this knowledge with the immunohistopathological findings of the affected organs for a personalized decision-making process for each patient is proposed.